Skip to main content

Sudden death with trimethoprim-sulfamethoxazole while on ACE-inhibitor or ARBs




What? It’s already 2015. But, I have so many great articles published in 2014 that I need to post about! Well then, for my next series of posts I’m going to do a quick round-up of articles published last year that we haven’t already talked about on GeriPal.   This first on the list shows an association between sudden death in those who were given trimethoprim-sulfamethoxazole (co-trimoxazole) while already on renin-angiotensin system blockers (i.e. angiotensin converting enzyme inhibitors (ACE-inhibitors) and angiotensin receptor blockers (ARBs).

The Study

This was a large nested case-control study published in the BMJ last year.  It included residents of Ontario who were 66 years of age or older and were treated with an ACE-inhibitors or ARBs.   The cases were those who had sudden death and who received an outpatient prescription for either co-trimoxazole, amoxicillin, ciprofloxacin, norfloxacin, or nitrofurantoin within 7 days of death.  Each case was matched with up to four controls on age, sex, presence of kidney disease, and diabetes.

The Results

Of the 1,601,542 patients in this cohort treated with either an ACE-inhibitor or ARB, 39,879 died suddenly.  Of these deaths, 1,110 occurred within seven days of a prescription for one of the study antibiotics.

In the primary analysis, trimethoprim/sulfamethoxazole was associated with a significantly increased risk of sudden death compared those who received of amoxicillin (odds ratio 1.38, 95% confidence interval 1.09 to 1.76 after adjustment). Ciprofloxacin also had a smaller but still significant increased risk of sudden death compared to those taking amoxicillin (1.29, CI of 1.03 to 1.62).

So What?

Now we don't really know if there is a causal relationship between use of trimethoprim-sulfamethoxazole and sudden death, and we can only speculate on what may be the reasons behind the association. The authors hypothesize that it is due to trimethoprim’s ability to raise potassium levels. However, we don't have any data on serum potassium concentrations. There are also limitations to this trial that prevent a definitive answer to what we are supposed to do clinically. For example, the cases and controls were very different (the cases were more likely to have heart failure, renal failure, and all together more co-morbidities). There also may be an issue of confounding by indication, as we don't have any data on why these individuals were prescribed these antibiotics.

Again, so what?

So, what do we do with this information? I’ll be more cautious when prescribing trimethoprim-sulfamethoxazole, especially in those taking ACE-inhibitors and ARBs. In a previous publication by the authors of this study, there was a seven sevenfold increase in the risk of hyperkalemia induced hospital admissions in ACE-inhibitors and ARB users taking trimethoprim-sulfamethoxazole compared with those exposed to other antibiotics. So at a very minimum, I'll keep a closer eye on those potassium levels.

by: Eric Widera (@ewidera)

For a more in-depth discussion on this paper, check out the editorial here or this wonderful post on #NephJC.


Comments

Popular posts from this blog

Dying without Dialysis

There is a terrific article in this weeks Journal of Pain and Symptom Management by Fliss Murtagh of King's College in London about the epidemiology of symptoms for patients with advanced renal failure who die without dialysis.  This study is important because while we know that patients with advanced renal failure have a limited life expectancy and the average age of initiation of hemodialysis is increasing, we know little about the alternatives to hemodialysis.  Specifically, we know nothing about symptoms affecting quality of life among patients who elect not to start dialysis (so called "conservative management" - is this the best label?).  This article provides a terrific counterpoint to the article in last years NEJM showing that nursing home residents who initiated hemodialysis tended to die and decline in function (see GeriPal write up here). 

The study authors followed patients with the most advanced form of chronic kidney disease (the new name for renal failu…

Language Matters: Podcast with Brian Block and Anna DeForest

One of our first GeriPal posts was titled "Rant on Terminology," by Patrice Villars, NP.  In the spirit of looking back over our first 10 years, here is the opening paragraph to that post:

News Headlines read: Sen. Edward Kennedy loses battle with cancer. Really, he lost? I thought he died from a malignant brain tumor, an “aggressive” brain tumor. The median survival is less than a year for people for his particular tumor. Kennedy was diagnosed in May of 2008. He lived over 15 months after diagnosis. What a loser. He must not have fought hard enough. Huh? I thought he spent most of his life battling for social and health care reform in America. In this week's GeriPal podcast we take a deeper dive into this issue of language and medicine.  We are joined by guests Anna DeForest, MD, MFA, a resident in Neurology at Yale, and Brian Block, MD, a pulmonary critical care fellow at UCSF.  

Anna recently published a paper in the NEJM describing her reaction to hearing terms like, &…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …